menu
    • menu
    [{"orgOrder":0,"company":"Endpoint Health","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Endpoint Health","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Endpoint Health \/ Endpoint Health","highestDevelopmentStatusID":"4","companyTruncated":"Endpoint Health \/ Endpoint Health"},{"orgOrder":0,"company":"Endpoint Health","sponsor":"Mayfield","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Endpoint Health","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Endpoint Health \/ Mayfield","highestDevelopmentStatusID":"4","companyTruncated":"Endpoint Health \/ Mayfield"}]

    Find Clinical Drug Pipeline Developments & Deals by Endpoint Health

    Menu

    Endpoint Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Endpoint Health

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Endpoint Health

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antithrombin III

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Mayfield

                            Deal Size : $52.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Endpoint Health Raises $52 Million in Financing to Expand and Progress Precision Immunology Pipeline

                            Details : Proceeds from the financing round will be used to extend the company’s Precision-First platform and expand its therapeutic pipeline and will be used to advance Antithrombin III, the company’s first precision therapy, to a Phase II clinical trial for ...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 02, 2022

                            Lead Product(s) : Antithrombin III

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Mayfield

                            Deal Size : $52.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Endpoint Health

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Endpoint Health

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antithrombin III

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Grifols International

                            Deal Size : $25.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Grifols Signs Global Collaboration Agreement with Endpoint Health to Develop and Commercialize Antithrombin II...

                            Details : As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of Antithrombin III (AT-III), a plasma protein that treats patients with blood clotting issues.

                            Product Name : AT-III

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 24, 2022

                            Lead Product(s) : Antithrombin III

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Grifols International

                            Deal Size : $25.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth